Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment

AIDSmeds.com: "A nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen consisting of Kaletra (lopinavir and ritonavir) plus Isentress (raltegravir) is comparable with a standard regimen consisting of Kaletra plus Truvada (tenofovir and emtricitabine) in people living with HIV starting antiretroviral (ARV) therapy for the first time, according to 48-week study results reported Monday, July 19, at the XVIII International AIDS Conference in Vienna."